Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA.
Harvard Stem Cell Institute, Harvard University, Boston, MA.
Blood. 2021 Oct 14;138(15):1331-1344. doi: 10.1182/blood.2020007920.
The mechanism underlying cell type-specific gene induction conferred by ubiquitous transcription factors as well as disruptions caused by their chimeric derivatives in leukemia is not well understood. Here, we investigate whether RNAs coordinate with transcription factors to drive myeloid gene transcription. In an integrated genome-wide approach surveying for gene loci exhibiting concurrent RNA and DNA interactions with the broadly expressed Runt-related transcription factor 1 (RUNX1), we identified the long noncoding RNA (lncRNA) originating from the upstream regulatory element of PU.1 (LOUP). This myeloid-specific and polyadenylated lncRNA induces myeloid differentiation and inhibits cell growth, acting as a transcriptional inducer of the myeloid master regulator PU.1. Mechanistically, LOUP recruits RUNX1 to both the PU.1 enhancer and the promoter, leading to the formation of an active chromatin loop. In t(8;21) acute myeloid leukemia (AML), wherein RUNX1 is fused to ETO, the resulting oncogenic fusion protein, RUNX1-ETO, limits chromatin accessibility at the LOUP locus, causing inhibition of LOUP and PU.1 expression. These findings highlight the important role of the interplay between cell-type-specific RNAs and transcription factors, as well as their oncogenic derivatives in modulating lineage-gene activation and raise the possibility that RNA regulators of transcription factors represent alternative targets for therapeutic development.
普遍转录因子介导的细胞类型特异性基因诱导的机制,以及白血病中其嵌合衍生物引起的破坏,目前尚不清楚。在这里,我们研究了 RNA 是否与转录因子一起驱动髓系基因转录。在一个综合的全基因组方法中,我们调查了同时具有与广泛表达的 Runt 相关转录因子 1(RUNX1)的 RNA 和 DNA 相互作用的基因座,我们鉴定了来自 PU.1 上游调控元件的长非编码 RNA(lncRNA)(LOUP)。这种髓系特异性和多聚腺苷酸化的 lncRNA 诱导髓系分化并抑制细胞生长,作为髓系主调控因子 PU.1 的转录诱导剂。在 RUNX1 与 ETO 融合的 t(8;21)急性髓系白血病(AML)中,产生的致癌融合蛋白 RUNX1-ETO 限制了 LOUP 基因座的染色质可及性,导致 LOUP 和 PU.1 表达的抑制。这些发现强调了细胞类型特异性 RNA 和转录因子及其致癌衍生物在调节谱系基因激活中的重要作用,并提出了 RNA 转录因子调节剂可能是治疗开发的替代靶标的可能性。